Search Tips:
1. Search Adjacent Words - Place quotes around the exact keyword phrase you want to search. Ex: "regulatory environments"
2. Search in Title Only - Type title: and surround the search terms in quotations to specifically search in titles. Ex: title:"regulatory environments" close
|
IP Updates
Teva Pharmaceuticals USA, Inc. v. Novartis Pharmaceuticals Corp.
Teva Pharmaceuticals USA, Inc. v. Novartis Pharmaceuticals Corp., 482 F.3d 1330 (Fed. Cir. 2007)
The Federal Circuit reverses dismissal of declaratory judgment action, again relying on the Supreme Court's decision in MedImmune v. Genentech, 127 S.Ct. 764 (2007). The Federal Circuit analyzed MedImmune and announced that it would be applying an "all the circumstances" standard to find an injury-in-fact for declaratory judgment jurisdiction (rather than its former two-part test). The Federal Circuit found that Teva had shown an actual controversy under the Declaratory Judgment Act, 28 U.S.C. § 2201(a).
In his concurrence, Senior Judge Friedman indicated that "[i]n these unusual circumstances, where the Supreme Court went out of its way to state its disagreement with our ‘reasonable apprehension of imminent suit' test, which was not an issue in the case before it, it appears incumbent on us to stop using that test and hereinafter to apply the general declaratory judgment standards that the Supreme Court applied in MedImmune." 482 F.3d at 1347. Detailed Case Summary Opinion
|
|